“One of the strongest associations was with FLT3-ITD status, suggesting that many of the poor outcomes ascribed with FLT3 mutations are probably related toUBTFtandem duplications,” adds Klco. FLT3-ITD mutations are among the most common mutations in pediatric AML. Bon...
Background and aims The better understanding of the molecular basis of Acute Myeloid Leukemia (AML) allowed to identify critical gene mutations related to a higher risk of treatment failure in patients receiving conventional 3+7 chemotherapy. Consequently, the presence of at least one mutation among...
In conclusion, prophylactic therapy with epigenetic agents may improve long-term prognosis and is well-tolerated in patients with RUNX1::RUNXT1-positive high-risk AML. Timely post-transplant prophylactic therapy may be more effective than preemptive therapy based on positive MRD results. This is a...
Scientists previously thought mutations in myeloid genes could only cause myeloid cancers such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)—hence the name given to these genes. However, a recent study led by researchers at the University of Chicago Medicine reveals that myeloid...
In AML, TP53 mutations or chromosomal aberrations affecting the short arm of chromosome 17 are predominantly found in MDS- or therapy-related acute myeloid leukemia [6, 7] and predict for a higher risk of therapy failure and an adverse survival outcome [1, 8]. However, most de novo AML ...
In this phase I trial, 51 newly diagnosed non-favorable risk AML and high-risk MDS patients were enrolled and treated with AcDVP16 (cytarabine 667 mg/m2/day IV continuous infusion days 1–3, daunorubicin 45 mg/m2 IV days 1–3, etoposide 400 mg/m2 IV days 8–10) induction ...
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non
Targeted molecular therapies, novel cytotoxics, and immune-based therapies are under investigation for the management of high-risk AML. Some of the agents covered include tyrosine kinase inhibitors targeted to AML specific oncoproteins, nanoparticle formulations of existing drugs, nucleoside analogs, ...
The rationale behind the SAVE study was to assess a combination of revumenib, ASTX727 and venetoclax in patients with relapsed/refractory AML to potentially improve chances of responses and decrease relapse risk, according to the presentation. Issa noted in the presentation that hypomethylating ...
There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a